Results from the first phase 1 clinical trial investigating a preventive messenger RNA (mRNA) vaccine are in and the outlook for this alternative to inactivated vaccines is promising.
In the proof-of-concept nonrandomized rabies vaccine trial funded by German pharmaceutical company CureVac, mRNA vaccination with a needle-free injection device induced immunogenicity in 32 (71%) of 45 participants given doses intradermally and 6 (45%) of 13 participants given doses intramuscularly. Adverse effects were mostly mild or moderate, with a safety profile similar to inactivated vaccines, said study investigator Frank V. Sonnenburg, MD, a professor in the department of infectious diseases and tropical medicine at the University of Munich. One serious adverse reaction possibly related to the vaccination, a case of Bell palsy, resolved on its own.
Abbasi J. First Phase 1 Trial of a Prophylactic mRNA Vaccine Reported. JAMA. 2017;318(22):2173. doi:10.1001/jama.2017.19065
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: